PPA
LRMR icon

Parametric Portfolio Associates’s Larimar Therapeutics LRMR Stock Holding History

Parametric Portfolio Associates’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,048
Closed -$34K – 3984
2019
Q1 		$34K Buy
1,048
+7
+0.7% +$359 ﹤0.01% 3898
2018
Q4 		$62K Sell
1,041
-119
-10% -$11.7K ﹤0.01% 3831
2018
Q3 		$163K Buy
1,160
+71
+7% +$8.62K ﹤0.01% 3794
2018
Q2 		$134K Sell
1,089
-55
-5% -$4.67K ﹤0.01% 3775
2018
Q1 		$102K Sell
1,144
-165
-13% -$14K ﹤0.01% 3857
2017
Q4 		$73K Sell
1,309
-4
-0.3% -$180 ﹤0.01% 3849
2017
Q3 		$55K Sell
1,313
-269
-17% -$11.2K ﹤0.01% 3990
2017
Q2 		$67K Sell
1,582
-821
-34% -$42K ﹤0.01% 3951
2017
Q1 		$134K Buy
2,403
+861
+56% +$42.7K ﹤0.01% 3671
2016
Q4 		$59K Buy
1,542
+545
+55% +$22.1K ﹤0.01% 3732
2016
Q3 		$40K Buy
+997
New +$45.3K ﹤0.01% 3736

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parametric Portfolio Associates's LRMR Position: Q2 2019 in Review

Parametric Portfolio Associates sold out of Larimar Therapeutics (LRMR) in Q2 2019, closing a stake of 1,048 shares — an estimated $34K sold.

Parametric Portfolio Associates first reported a position in LRMR in Q3 2016 and held it in 11 quarters. The position peaked at $163K in Q3 2018. 71 funds tracked by Wall St. Rank hold LRMR as of Q2 2019.

  • Parametric Portfolio Associates reported no remaining Larimar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Parametric Portfolio Associates sold 1,048 Larimar Therapeutics shares in Q2 2019, an estimated $34K.
  • Parametric Portfolio Associates first reported a position in Larimar Therapeutics in Q3 2016 and held it in 11 quarters.
  • Parametric Portfolio Associates's Larimar Therapeutics position peaked at $163K in Q3 2018.
  • 71 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2019.

Based on Parametric Portfolio Associates's 13F filing for Q2 2019, filed 13 Aug 2019.